Kremoint Pharma Private Limited - Due diligence report

A 360° intelligence report on Kremointpharma: trust score, financial health, credit view, compliance, directors, growth and distress signals…

1992-05-12 Ambernath, Maharashtra Active Unlisted Active Compliant
Share
KP Kremoint Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Kremointpharma — 360° Intelligence Report

Generated from MCA filings & public records
92/100
Trust Score
Low Risk

Kremointpharma is assessed as Low Risk with a Trust Score of 92/100. Kremointpharma is an active private limited indian non-government company incorporated in 1992, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Kremoint Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
92/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
86/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.
  • Externally credit-rated (A3).

Charges position: 2 open (1.01 cr) · 14 satisfied (42.29 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others9 48.0 cr
The Bharat Co-Operative Bank(Mumbai) Ltd4 48.0 cr
The Bharat Cooperative Bank (Mumbai) Ltd1 48.0 cr
The Bharat Co-Operative Bank (Mumbai) Limited1 48.0 cr
Hdfc Bank Limited1 48.0 cr
Compliance Score: 86/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 2 court forum(s).
  • 2 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
VIBHA GAGAN SHARMA 01234567 Director 01/04/2018 6 yrs Approved
BHADRESH KESHAVJI THAKKAR 01234567 Director 01/04/2018 6 yrs Approved
Yesha Bhadresh Thakkar 01234567 Director 01/04/2018 6 yrs Approved
SHRUTI VISHAL RAO 01234567 Director 01/04/2018 6 yrs Approved
Vishal Vijay Rao 01234567 Director 01/04/2018 6 yrs Approved
  • 5 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Bliss Gvs Pharma Limited
Subsidiaries
1
Group entities
1
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Eipii Exports Private Limited Subsidiary Company 74.00%
Bliss Gvs Pharma Limited Holding Company 74.00%

Key managerial personnel: BHADRESH KESHAVJI THAKKAR (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Net margin improved to 61%.
EPFO headcount growing - hiring signal.
Operating for 34+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
2 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence89/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment93/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 1.01 cr already registered.
  • Compliance record supports lending.
Investor view94/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
04 Nov 2025
Charge satisfied
Others
06 Sep 2025
Charge satisfied
Others
02 Jul 2025
Last AGM held
Annual general meeting
01 Jul 2025
Director ceased
Vishal Vijay Rao
31 Mar 2025
Latest balance sheet
Filed with ROC
15 Jan 2025
Director appointed
Vishal Vijay Rao (Director)
08 Jan 2025
Charge created
Others - 4.00 cr
20 Jul 2024
Director appointed
Yesha Bhadresh Thakkar (Director)
Director appointed
SHRUTI VISHAL RAO (Director)
02 Feb 2024
Charge created
Others - 5.00 cr
11 Jul 2023
Charge created
Others - 1.00 Lakh
27 May 2023
Charge created
Others - 1.00 cr
08 May 2023
Charge satisfied
Hdfc Bank Limited
23 Dec 2022
Charge satisfied
Others
27 Jun 2022
Director ceased
GAGAN SHARMA HARSH
10

Key Observations

Auto-generated from the data above
Revenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
5 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of A3 from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Mega Innovative Crops Private Limited U24239GJ2008PTC053246 Ankleshwar, Gujarat, India
Iscon Surgicals Limited U24232RJ1991PLC005963 Jodhpur, Rajasthan, India
M S Healthcare U24239MH2001PTC130893 Mumbai, Maharashtra, India
Dhanlakshmi Biochem Private Limited U01403MH2013PTC243222 Mumbai, Maharashtra, India
Athenadds U24230MH1995PTC094546 Mumbai, Maharashtra, India
Meghna Colour Chem Private Limited U24299GJ2021PTC123491 Vapi, Gujarat, India
Perfect Polychem Private Limited U51496DL2001PTC110505 New Delhi, Delhi, India
Synaptics Labs Private Limited U24304TG2018PTC127623 Shaikpet, Telangana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Kremointpharma before audits and certifications: compliance score 86/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Kremointpharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Kremointpharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 92/100, distress signals and MSME payment-delay disclosures - know whether Kremointpharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Kremointpharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Kremointpharma an active company?

Kremointpharma has MCA status “Active” with a compliance score of 86/100 (Low Risk).

Is Kremointpharma financially healthy?

Kremointpharma has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Kremointpharma?

Its overall Trust Score is 92/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Kremointpharma?

The ultimate holding entity is Bliss Gvs Pharma Limited. 5 active director(s) are on record.

Does Kremointpharma have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 14 earlier charge(s) stand satisfied.

Is Kremointpharma up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 86/100 (Low Risk).

Is it risky to lend to Kremointpharma?

Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.